Neurologic disorders

Published on 20/03/2015 by admin

Filed under Critical Care Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1229 times

CHAPTER 7 Neurologic disorders

General neurologic assessment

Assess motor and cerebellar function

Evaluate bilaterally (both sides of body, both arms and legs) for muscle size, strength, tone, and coordination. Note muscle atrophy or hypertrophy.

MUSCLE STRENGTH RATING
Score Description of Strength
5/5 Patient moves joint with full ROM against normal resistance and gravity
4/5 Patient moves joint with full ROM against mild resistance and gravity
3/5 Patient moves joint with full ROM against gravity only
2/5 Patient moves joints with full ROM but not against gravity
1/5 Patient’s muscle contracts in an attempt to move joint; joint does not move
0/5 Patient does not visibly attempt to move; no muscle contraction; paralysis

ROM, Range of motion.

Motor deficits (weakness or paralysis) are caused by injury or edema to the primary motor cortex and corticospinal (pyramidal) tracts.

Sensory assessment

Sensory deficits occur when the primary sensory cortex, the sensory association areas of the parietal lobe, or the spinothalamic tracts are injured or edematous. Sensory deficits include inability to distinguish objects according to characteristics (e.g., size, shape, weight) and inability to distinguish overall changes in temperature, touch, pressure, and position.

Improvement in both motor and sensory perception may be seen as cerebral edema subsides.

Dysphagic screening

Should be performed early, particularly when stroke has occurred, to prevent complications of aspiration and to initiate appropriate nutritional therapy. People with neurologic dysfunction are poor judges of their own ability to swallow, so a thorough evaluation and intervention by a speech pathologist may be required, following routine screening procedures recommended by institutional protocol.

Diagnostic Tests for Neurologic Disorders

Test Purpose Abnormal Findings
Cerebral angiography Digital subtraction angiography visualizes blood flow.
Involves use of intravascular catheter
The gold standard for evaluating cerebral vasculature
Invasive procedure with minimal risk used to visualize the cerebral blood vessels
Areas of reduced cerebral blood flow, aneurysms, arteriovenous malformations (AVMs), vascular abnormalities
Used with interventional neuroradiologic procedures such as coiling, AVM embolization (gluing)
Provides specific information on the cause of stroke by identifying the blood vessel involved
Computed tomography (CT) of brain Performed emergently, is the gold standard of differentiating ischemic from hemorrhagic stroke; may be done at intervals to monitor progress
Assess details of structures of bone, tissue, and fluid-filled space.
Detects exudate, abscesses, and intracranial pathology (e.g., tumors, brain injury)
Assess for hydrocephalus.
Shift of structures due to enlarged mass, edema, exudate, abscesses, fresh hemorrhage, hematomas, infarction, hydrocephalus
Can visualize facial skeleton and soft tissue structures for abnormalities (e.g., tumors, brain injury)
Within the first few hours after an acute ischemic stroke, the scan may appear normal. Intracranial hemorrhage is easily diagnosed on CT—blood appears as a bright white signal.
Continuous electrocardiographic (ECG) monitoring Evaluate cardiovascular status, especially during medication administration. Phenytoin and other AEDs can cause dysrhythmias and hypotension.
CT angiography Less invasive than cerebral angiography; involves use of contrast media injection into peripheral vein and use of CT scanner Visualize intra-arterial clot, small intracranial aneurysm, AVM
CT perfusion or CT-xenon scan (CTP) Provides information related to cerebral blood flow (CBF)and volume
Used to guide clinical decision making regarding the use of thrombolysis or interventional procedures
Compromised blood flow; a limited test; cannot detect infarcted tissue
Electroencephalography (EEG) Evaluate the brain’s electrical activity for ongoing seizures, even if there are no clinical signs of seizures. Diagnosis of seizures and localization of structural abnormalities
Also used as element of criteria for brain death
Electromyography (EMG) or nerve conduction velocity (NCV) Assesses nerve conduction velocity deficit as a result of the demyelination of peripheral nerves EMG and NCV demonstrate profound slowing of motor conduction velocities and conduction blocks several weeks into the illness.
Lumbar puncture (LP) with cerebrospinal fluid (CSF) specimen for analysis Measures CSF pressures and obtains CSF specimen when infection, such as meningitis or neurosyphilis, is suspected
May be performed when SAH is suspected and CT is normal
Elevated protein, low glucose, elevated WBC
Magnetic resonance imaging (MRI) of brain Minute oscillations of hydrogen atoms in brain create graphic image of bone, fluid, and soft tissue
Provides a more detailed image
MRI is most useful for ischemic patients in identifying the cause and area involved.
Provides detailed information regarding the area of injury or its vascular supply (MRA)
Diffusion-weighted imaging (DWI) is a measurement of edema, whereas perfusion weighted imaging (PWI) is a measurement of global CBF.
Infarcts, areas at risk or ischemic areas, vascular defects, stenosis, occlusion
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) To evaluate brain metabolism and blood flow using three-dimensional imaging produced using a radioactive tracer Demonstrates abnormal function of the brain by revealing abnormal structures, metabolism, and perfusion
Locates areas of brain causing seizures, head injury, and some disorders (e.g., Alzheimer’s)
Radioisotope brain scan Examine areas of blood flow through concentration of isotope uptake in the brain. Increased or decreased blood flow intraoperatively or assess for postoperative cerebral infarction
Lack of uptake may indicate cerebral brain death.
Transcranial Doppler Noninvasive and can be done serially at the bedside
Evaluates the intracranial vessels and assesses the velocity of blood flow in the anterior and posterior cerebral circulation
Also used to evaluate vasospasm, to determine brain death via detection of cerebral circulatory arrest, for intraoperative monitoring, and to locate emboli
Arterial narrowing
vasospasm, cerebral circulatory arrest, emboli due to vasospasm
Can also be used to confirm absent blood flow in brain death

Brain death

Pathophysiology

Brain death is defined as irreversible loss of function of the brain, including the brainstem and respiratory centers. Cardiac death is the cessation of mechanical action/pumping of the heart, resulting in absence of pulse, heart sounds, blood pressure, and respirations. Brain death is most frequently the result of increased intracranial pressure (ICP) caused by severe traumatic head injury or hemorrhagic stroke caused by ruptured cerebral aneurysm with subarachnoid hemorrhage (SAH) or intracranial hemorrhage (ICH). A significant number of patients with large acute ischemic strokes (AIS) experience cerebral edema and herniation. Hypoxic-ischemic encephalopathy with massive brain swelling after prolonged cardiopulmonary resuscitation or asphyxia and encephalopathy with cerebral edema resulting from fulminant hepatic failure may also result in increased ICP, herniation, and brain death.

If brain death occurs quickly, cardiac death may occur immediately. If brain death occurs more slowly, with time to initiate mechanical ventilation prior to cardiac death, the heart can continue to beat/pump since the cardiac pacing cells operate independently from brain regulation. Mechanical ventilation provides the oxygen necessary to maintain the pacing cells if the patient is circulating adequate amounts of blood cells carrying oxyhemoglobin, acidosis is controlled, and electrolytes are managed. Over time, without a functional hypothalamus and pituitary gland, patients experience further instability of blood pressure due to loss of regulation of the thyroid and adrenal glands. Massive diuresis is common when the posterior pituitary gland ceases to function. If the patient is an organ donor, the organs must be sustained prior to removal, requiring management of all sequelae of brain death. Guidelines for managing brain dead organ donors have common elements internationally, with most controversy stemming from the need to provide additional hormones to help control endocrine-related crises associated with loss of function of the pituitary and hypothalamus and use of prophylactic antibiotics to prevent infection.

Neurologists or neurosurgeons may diagnose brain death approximately two to three times monthly in large referral centers. Herniation, or displacement of a portion of the brain through openings in the intracranial cavity, results from increased ICP. Herniation occurs when there is difference between the cranial compartment pressures above (supratentorial) and below (infratentorial) the tentorium, the rigid membrane that divides the skull. If additional blood or cerebrospinal fluid (CSF), edematous tissue, or tumor occupies space inside the skull, there is little ability to expand to “make room” for anything not normally present. These “mass lesions” or “space-occupying lesions” cause “crowding” within their cavity, which increases the pressure.

When pressure in one of the two compartments (supratentorial or infratentorial) is markedly elevated, the brain structures and blood vessels within the cavity are compressed, resulting in ischemia, hypoxia, and, if uncontrolled, cerebral anoxia. When blood flow is minimal to absent, the hypoxic/anoxic brain tissues become more edematous. Eventually, no space remains for further expansion. The skull cannot expand and the tentorium expands minimally, so the brain is forced through the available openings. The movement or displacement through an opening causes further compression of blood vessels, with possible laceration and destruction, which leads to necrosis of brain tissues and brain death (see Traumatic Brain Injury, Neurologic Herniation Syndromes, p. 333).

Neurologic assessment: brain death

Making the diagnosis of brain death

The three cardinal signs/symptoms in brain deat h are coma, absent brainstem reflexes, and apnea according to the AAN guidelines. Patients must have all three findings to be considered dead (brain dead patients are dead). There should be at least two separate clinical examinations, preferably by a neurologist, with at least 2 hours between examinations. If clinical uncertainty is present, two different physicians, preferably neurologists, should examine the patient following completion of appropriate diagnostic testing to ensure patient has not overdosed on a drug; has ingested a poison; has undiagnosed endocrine system dysfunction, electrolyte imbalance, or dehydration; and is free of untreated significant hypoxia, hypercapnia, or acidosis. Adherence to the AAN guidelines varies among the large medical centers in the United States. Diabetes insipidus, myxedema coma, and adrenal crisis may result from loss of the hypothalamic/pituitary regulatory axis as part of brain death. Large amounts of dextrose-containing IV fluids and insulin resistance may prompt hyperglycemia.

DIAGNOSTIC TESTS FOR BRAIN DEATH

Test Purpose Abnormal Findings
Arterial blood gas (ABG) analysis Assesses for acidosis resulting from abnormal gas exchange or compensation for metabolic derangements Low pH: Acidosis may reflect respiratory failure or metabolic crisis.
Carbon dioxide: Elevated CO2 or hypercapnia reflects respiratory failure; decreased CO2 may reflect compensation for metabolic acidosis.
Hypoxemia: PaO2 less than 80 mm Hg
Oxygen saturation: SaO2 less than 92%
Bicarbonate: HCO3−less than 22 mEq/L
Base deficit: less than –2
Apnea test

PaO2, PCO2, and pH are measured after approximately 8 minutes; the ventilator is reconnected after the ABG sample is drawn.

Validates absence of spontaneous respirations while ventilator is disconnected; test is designed to be completed safely, to avoid inducing cardiopulmonary instability during the procedure: Confirmatory findings
The apnea test is positive if:

The apnea test is negative if:

Note: If the patient has severe facial trauma, preexisting abnormal pupils, sleep apnea, severe lung disease resulting in chronic hypercapnia (CO2 retention), or toxic levels of any sedative drugs, aminoglycosides, tricyclic antidepressants, anticholinergics, antiepileptic drugs, chemotherapeutic agents, or neuromuscular blocking agents, additional testing may be required to confirm brain death. Additional confirmatory tests are not mandatory if the clinical diagnosis is positive (patient is unresponsive/in a coma, brainstem reflexes are absent, apnea test is positive). Cerebral angiography Assesses if cerebral perfusion is present Absent perfusion: No intracerebral blood filling is present at the level of the carotid bifurcation or circle of Willis. Electroencephalography (EEG) Assesses level of electrical activity of the brain (brain wave analysis) No signs of viability: No electrical activity during at least 30 minutes of recording, which meets the minimal technical criteria of EEG recording for brain viability; test adheres to American
Electroencephalographic Society criteria for those with suspected brain death. Transcranial Doppler ultrasonography Assesses for presence of cerebral perfusion and degree of vascular resistance using Doppler signals
Positive findings indicate very high vascular resistance resulting from markedly increased ICP. No functional blood flow: Small systolic peaks corresponding with early systole without diastolic flow or reverberating flow. Note: 10% of patients do not have temporal windows appropriate for transmitting ultrasound signals. Initial absence of Doppler signal does not confirm brain death. Cerebral perfusion scan using technetium-99m hexamethapropyleniamineoxime Assesses for cerebral circulation and brain cell viability using uptake of isotope as the criteria No circulation/no uptake: No uptake of isotope by brain cells (“hollow skull phenomenon”) Somatosensory evoked potentials Assesses for normal brain responses to electrical stimulation No response: Bilateral absence of N20-P22 response with median nerve stimulation

Collaborative management

ORGAN DONOR MANAGEMENT FOLLOWING BRAIN DEATH

Once brain death has been diagnosed, the organ removal team may begin preparations for organ removal within 5 minutes under ideal conditions. If the death was unanticipated, or organ donation was not discussed or controversial, additional time is needed for approaching the donor’s family/significant other(s) regarding donation. The parameters below must be managed in order to provide the best opportunity to recover viable organs from the donor.
Physiologic Parameter Intervention
Maintain blood pressure. MAP 60 to 70 mm Hg: maintain euvolemia; administer vasopressor agents (e.g., norepinephrine) if needed.
Monitor organ perfusion. Monitor urine output and lactate level; consider hemodynamic monitoring with a pulmonary artery catheter.
Balance electrolytes. Monitor electrolytes (Na+, K+) every 2 to 4 hours; correct to normal range.
Control diabetes insipidus. Suspected diabetes insipidus (urine output more than 200 ml/hr, rising serum sodium): administer DDAVP (e.g., 2 to 4 mcg IV in adults) and replace volume loss with 5% dextrose.
Manage hyperglycemia. Treat hyperglycemia: keep blood glucose 100 to 180 mg/dl.
Control hypothermia. Keep temp greater than 35°C. Early use of warming blankets to prevent declining temperature is helpful; hypothermia is difficult to reverse once developed.
Ventilate and oxygenate. Provide ongoing respiratory care: frequent suctioning, positioning/turning, PEEP, alveolar recruitment strategies.
Manage anemia. Maintain hemoglobin at greater than 8 g/dl.
Control hormonal imbalances causing hemodynamic instability. Consider hormonal replacement therapy if volume resuscitation and low-dose inotropes are ineffective for maintaining BP and/or if cardiac ejection fraction is less than 45%.
Typical regimens include:
Triiodothyronine (T3): 4 mcg IV bolus, then 4 mcg/hr by IV infusion
Arginine vasopressin (AVP): 0.5 to 2.4 units/hr to maintain MAP 60 to 70 mm Hg
Methylprednisolone: 15 mg/kg IV single bolus

From the Australasian Transplant Coordinators Association Inc: National guidelines for organ and tissue donation, ed 3. 2006. http://www.atca.org.au/files/ATCAguidelinesonlineoct06.pdf

Care priorities

3. Discuss organ donation only after the clinical diagnosis of brain death has been made and the family understands the patient is dead.

Contact with the organ procurement organization should be done in a timely manner when death is imminent. Collaborate with the organ procurement organization to enhance the experience of the donation process. Do not broach the subject of donation or hint about donation prior to the time the patient has been pronounced dead, unless the patient had resolved the issue of organ donation with the family prior to death. The subject of organ donation is generally better discussed after the patient has been pronounced dead and the family understands that despite the patient having a beating heart, without mechanical ventilation, cardiac death will ensue. Choose a quiet, private, comfortable place to discuss organ donation, ideally leaving the lead role to a professional from the organ procurement agency. The family requires privacy, so they can express their grief regarding the death and can be left alone to discuss donation, if needed. Ensure all members of the team participating in the discussion are introduced to family members. All family members/significant others should be introduced to the team by name, and their role in the family/life of the deceased should be explained. Only those whom the next of kin requests to be present should participate in the discussion. Adequate time should be given asking/answering questions. The words used during the discussion are very important:

5. Discontinue life support after the family has had time to visit the patient, if the family declines the opportunity to donate the patient’s organs.

Weaning of mechanical ventilation and vasoactive drugs is unnecessary because the patient is dead. Reasons for declining donation generally relate to the wishes of the patient, religious convictions, fear of disfigurement/mutilation of the patient’s body, and mistrust of the motives or anger with the procurement team members. Mistrust and anger often ensue if the family is improperly approached regarding organ donation. Involving the experienced health care professionals from the organ procurement team has been shown to yield a higher success rate with donation.

CARE PLANS FOR BRAIN DEATH

Decreased intracranial adaptive capacity

related to increased intracranial pressure resulting from imminent brain death. When brain death is imminent, mechanisms that normally compensate for increases in intracranial pressure are failing. When failed, brain herniation occurs.

Goals/outcomes

Patient is maximally supported for reduction of ICP until efforts are proved futile, when brain herniation ensues, resulting in brain death. Following brain death, hemodynamic status is supported until decisions are made regarding organ donation and/or discontinuation of life support.

image

Tissue Perfusion: Cerebral; Neurological Status: Consciousness.

Decisional conflict

related to the uncertainty regarding the proper course of action related to the discontinuation of life support and possible organ donation following brain death

Goals/outcomes

Family/support system is maximally supported in making judgments, and choosing between immediate discontinuation of life support, organ donation, or possibly continuing life support until information about brain death can be processed and accepted.

image

Decision Making; Information Processing; Dignified Life Closure; Acceptance: Health Status

Coping enhancement

1. Assess the impact of the patient’s life situation on roles and relationships within family/support system.

2. Use a calm, reassuring approach.

3. Provide factual information concerning diagnosis, treatment, and prognosis.

4. Seek to understand the family’s perception of the stressful situation.

5. Acknowledge the patient and significant others’ religious, spiritual, and cultural beliefs surround death, dying, and organ donation.

6. Encourage gradual mastery of the situation if resistance or denial is impacting the family’s ability to accept the diagnosis of brain death.

7. Ensure the family understands brain dead patients are dead. Patients are no longer able to breathe without mechanical ventilation, will experience cardiac death when removed from mechanical ventilation, will never regain consciousness, will never interact with others, and have no ability to experience joy related to human life.

8. Explain the difference between brain death, persistent vegetative state, and cardiac death. The family and significant others may have difficulty understanding why brain dead patients are different than those in coma who can recover from their insult/injury and those in a vegetative state who can recover brainstem function to begin breathing spontaneously. Families may not be able to comprehend why when the brain is dead, the heart still functions unless mechanical ventilation is removed. Guilt may be associated with removal of mechanical ventilation since the patient appears “alive” with mechanical ventilation in place.

imageEmotional Support; Environmental Management; Fluid/Electrolyte Management; Fluid Monitoring; Hypovolemia Management; Infection Control; Intravenous Therapy; Mechanical Ventilation; Positioning; Surveillance; Respiratory Monitoring; Spiritual Support; Vital Signs Monitoring

Additional nursing diagnoses

As appropriate, see nursing diagnoses and interventions in Nutritional Support (p. 117), Acute Respiratory Failure (p. 383), Mechanical Ventilation (p. 99), Prolonged Immobility (p. 149), and Emotional and Spiritual Support of the Patient and Significant Others (p. 200).

Cerebral aneurysm and subarachnoid hemorrhage

Pathophysiology

An aneurysm is a localized dilation of an arterial lumen caused by weakness in the vessel wall—90% of cerebral aneurysms are berry or saccular, while the other 10% are fusiform, traumatic, septic, dissecting, and Charcot-Bouchard aneurysms. Recent research suggests that cerebral aneurysms result from degenerative vascular diseases complicated by hypertension and atherosclerosis. Aneurysms most often occur at the bifurcation of the blood vessels of the circle of Willis, with 85% in anterior cerebral circulation and 15% in posterior cerebral circulation. Approximately 25% of patients have multiple aneurysms.

The critical care nurse may care for a patient with an unruptured aneurysm or a patient who is post rupture and has a diagnosis of subarachnoid hemorrhage (SAH). Unruptured aneurysms may be asymptomatic, but nearly half of the affected population experiences some warning sign or symptom prior to rupture as a result of expansion of the lesion and compression of cerebral tissue. When rupture occurs, an SAH into the subarachnoid space (SAS) and basal cisterns results. If the patient survives the initial compromise of cerebral circulation from the force of hemorrhaging arterial blood, with sharply increased ICP, the next challenge is the possibility of rebleeding and cerebral arterial vasospasm. The greatest incidence of rebleeding is between 3 and 11 days after SAH, with the peak at day 7. Mortality is about 70% overall from aneurysmal SAH. Theories regarding the cause(s) of rebleeding involve the normal process of clot dissolution coupled with fluctuations in arterial pressure.

The major complication for which the critical care nurse monitors post rupture is the occurrence of delayed cerebral ischemia from cerebral arterial vasospasm, in which the constriction of the arterial smooth muscle layer of the major cerebral arteries causes a dramatic decrease in cerebral blood flow and leads to cerebral ischemia and progressive neurologic deficit. Vasospasm occurs in as many as 60% of patients 4 to 14 days following SAH, with incidence peaking between 7 and 10 days. The pathogenesis of cerebral vasospasm is poorly understood, but ongoing research indicates it may be directly related to the amount of blood in the SAS and basal cisterns. The greater the volume of blood, the more pronounced is the risk of vasospasm. As clots in the basal cisterns begin to hemolyze, substances may be released that precipitate vasospasms. Current treatments include careful fluid balance, “triple H” (hypervolemia-hemodilution-hypertension) therapy, calcium antagonists, balloon or chemical angioplasty, and possibly cisternal fibrinolytic drugs. The patient with a ruptured cerebral aneurysm and SAH is also at risk for communicating or obstructive hydrocephalus, hypothalamic dysfunction, and hyponatremia.

Some patients present with an obstructive hydrocephalus from intraventricular blood, but communicating hydrocephalus develops in approximately 20% of patients with SAH as a result of the presence of blood in the SAS and ventricular system. The hydrocephalus may be acute (occurs within less than 24 hours), subacute (occurs within less than 4 hours to 1 week), or delayed (beginning 10 or more days after SAH). Blood in the SAS and ventricles obstructs the flow of CSF, interferes with circulation and resorption of CSF, and causes increased ICP, with concomitant worsening of neurologic status. In some patients, the hydrocephalus produces minimal symptoms and resolves without medical intervention, while others may require temporary or permanent diversion of CSF circulation to achieve symptom relief.

Hypothalamic dysfunction, seen in approximately one-third of patients with hydrocephalus after SAH, may result from mechanical pressure on the hypothalamus from a dilated third ventricle. The increased pressure causes an increase in the releasing hormones from the hypothalamus, which activates the hypothalamic-pituitary axis of the anterior pituitary as well as stimulating the production of antidiuretic hormone (ADH) by the posterior pituitary gland. The response to the increased adrenocorticotropic hormone (ACTH) from the anterior pituitary gland mimics an exaggerated stress response, which includes a marked increase in serum catecholamines leading to overstimulation of the sympathetic nervous system. The vasoconstrictive response is severe enough in a subset of patients to cause “stunned myocardium,” similar to what is seen with an acute myocardial infarction.

The surge of ADH from the posterior pituitary results in SIADH, which may include hyponatremia caused by cerebral salt-wasting syndrome, or a combination of factors influencing sodium and water metabolism (Table 7-1). Fluid management strategies in this patient population may be difficult (see Syndrome of Inappropriate Antidiuretic Hormone, p. 734). Hyponatremia may occur in 10% to 50% of patients with SAH. Untreated hyponatremia may lead to intracranial hypertension, cerebral ischemia, seizures, coma, and death.

Table 7-1 CLINICAL PRESENTATION WITH CEREBRAL SALT-WASTING SYNDROME VS SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE (SIADH)

Cerebral Salt-Wasting Syndrome SIADH
Hypotension Normotension
Postural hypotension Normotension
Tachycardia Normal pulse rate or bradycardia
Elevated hematocrit Normal or low hematocrit
Decreased glomerular filtration rate Increased glomerular filtration rate
Normal or elevated BUN and creatinine Normal or decreased BUN and creatinine
Normal or low urine output Normal or low urine output
Hypovolemia Normovolemia or hypervolemia
Dehydration Normal hydration
True hyponatremia Dilutional hyponatremia
Hypo-osmolality Hypo-osmolality
Decreased body weight Increased body weight

BUN, Blood urea nitrogen.

Note: Both hypothalamic dysfunction and hyponatremia are seen more frequently in patients with extensive SAH and are positively correlated with the subsequent development of cerebral vasospasm.

Neurologic assessment: cerebral aneurysm(s) and subarachnoid hemorrhage

History and risk factors

Research has shown that outcomes for patients with ruptured aneurysms and SAH have predictor indicators such as patient’s age, worst clinical grade on the Fisher Scale, the World Federation of Neurosurgeons Scale (WFNS), the Claassen Scale, the Ogilvy and Carter Scale, or the commonly used Hunt and Hess scale (see later). The Fisher Scale is predictive of the possibility of vasospasm, which is indicative of the amount of blood in the SAS. The Claassen grading system quantifies the risk of delayed cerebral ischemia from vasospasm associated with SAH. Unlike the Fisher scale, the Claassen scale considers the additional risk of SAH and intraventricular hemorrhage (IVH). The Claassen scale has not yet been prospectively validated. The WFNS grading system is widely used and includes objective terminology to determine grades. Similar to the Hunt and Hess scale, the data predictive power of the WFNS grades are inconsistent. The Ogilvy and Carter scale includes several features that may affect the outcome, including age, Hunt and Hess grade (clinical condition), Fisher grade (SAH volume and vasospasm risk), and aneurysm size, but it is more complicated to administer than Hunt and Hess and has been tested only on patients who have undergone aneurysm surgery. Patient outcomes are also related to aneurysm size, fever post SAH, and hyperglycemia on admission as a new finding affecting outcome. A noncontrast CT scan confirms the diagnosis of SAH by establishing the presence, amount, and location of blood in the SAS, the presence and degree of hydrocephalus, and the presence or absence of IVH or intraparenchymal hemorrhage.

Hunt and hess classification system:

Permits objective evaluation of progression of the patient’s initial symptoms. Used to predict clinical outcomes and for choosing treatments. Critical care nurses can benefit from using this grading system. Grading is performed according to symptom presentation and LOC.

The critical care nurse must carefully review the patient’s history and diagnostic findings to understand the potential risk for complications. Patients with unruptured aneurysms are at risk for rupture, but this depends on the location and size of the aneurysm. Unruptured aneurysms are usually found during a workup for headaches or other neurologic symptoms but may still produce symptoms of cerebral ischemia. A person with new onset of oculomotor nerve palsy, visual field loss, or lower cranial nerve deficits should be worked up for a potential aneurysm. Patients with unruptured aneurysms are typically encountered in the critical care setting after elective securing of the aneurysm. Additionally, some patients admitted for management of a ruptured cerebral aneurysm have additional unruptured aneurysms, which will be secured at a later date.

The typical distinguishing characteristic of a ruptured aneurysm is a patient who complains of the “worst headache of my life.” This is usually accompanied by severe nausea and vomiting, nuchal rigidity, visual disturbances, and photophobia. These patients are at high risk for rebleed within 24 hours. “Sentinel” or warning headaches are associated with an aneurysm that begins leaking days to weeks before rupturing. Very few patients manifest a sentinel headache prior to aneurysm rupture.

Rupture results in hemorrhage producing seizures, neurologic deficits, changes in LOC, and a high rate of mortality.

Intracranial pressure

Blood in the SAS can produce acute, subacute, or chronic hydrocephalus by blocking pathways for the resorption of CSF and leading to ventricular enlargement and nonfocal neurologic deterioration. Intraventricular extension at the time of aneurysm rupture can result in symptoms of acute hydrocephalus and will require temporary external ventricular drainage for management. Nuchal rigidity may be present even in the absence of hydrocephalus. Indicators of increased ICP are listed in Box 7-1.

Collaborative management

Care priorities

1. Pharmacotherapy

Calcium channel blocker: Nimodipine (Nimotop) inhibits calcium influx across the cell membrane of vascular smooth muscles. The resulting decrease in peripheral vascular resistance and vasodilation is believed to increase perfusion in cerebral vessels. While nimodipine does not prevent vasospasm, its use has been shown to be associated with improved long-term outcomes in patients who experience vasospasm. Nimodipine is given as 60 mg enterally every 4 hours for 21 days (the recommended course of therapy). Some patients experience significant decreases in BP with nimodipine and may require a dosing schedule of 30 mg every 2 hours. Intravenous (IV) administration of calcium antagonists is not supported in evidence at this time.

Antihypertensives: Antihypertensive therapy is used cautiously in this patient population because allowing hypertension is a significant element of standard therapeutic management in aneurysmal SAH. Hydralazine hydrochloride (Apresoline), labetalol (Normodyne), or nicardipine may be administered to control BP both prior to definitive securing of the ruptured aneurysm and after clipping or coiling to maintain BP in desired parameters.

Osmotic diuretics: Mannitol (Osmitrol), urea (Ureaphil), and glycerin (Glycerol) may be used to reduce ICP and treat cerebral edema via diuresis to remove fluid from the brain. Patients should be monitored for electrolyte imbalances, other systemic side effects, and adverse reactions related to fluid shifting.

Triple H therapy: Each of the following therapies may be used singly or in combination.

2. Surgical/endovascular intervention:

Initial management involves stabilizing the patient and minimizing the risk of re-rupture of the aneurysm. The National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), is recognized as the leader in research on the brain and nervous system in the United States. The NINDS sponsored the International Study of Unruptured Intracranial Aneurysms, including greater than 4,000 patients at 61 sites in the United States, Canada, and Europe. Results revealed the risk of rupture for aneurysms less than 7 mm in size is low. The findings provide a comprehensive evaluation of these vascular defects, offering guidance to both patients and health care professionals facing the difficult decision about the best treatment for a cerebral aneurysm.

Advances in imaging, use of microscopes intraoperatively, dedicated neurologic intensive care units, endovascular treatment methods, and aggressive cerebral vasospasm prevention and management have reduced morbidity and mortality. Treatment options depend on assessment of preoperative risk factors, predictive indicators, and location and size of the aneurysm. Successful treatments include endovascular embolization (“gluing”), surgical clipping, and endovascular detachable coiling.

Recent studies confirm improved patient outcomes when the ruptured aneurysm is secured within the first 24 to 72 hours for patients with grade I or II symptoms (Hunt and Hess Scale). Early intervention may prevent rebleeding, an often fatal complication, and allows for the management of vasospasm without risk of rebleeding. Securing of the aneurysm during the time period associated with the highest risk of development of cerebral arterial vasospasm has been shown to be associated with increased morbidity and mortality, so if the aneurysm is not secured within 24 to 72 hours of rupture, repair should be delayed until the peak time for vasospasm (7 to 10 days after SAH) has passed. Patients with grades III to V symptoms are generally considered poor interventional risks, especially in the period immediately after SAH. If these patients are clinically unstable, they may be treated medically until they improve or stabilize enough for endovascular or surgical intervention. Surgery is considered for a patient with a large intracranial clot causing life-threatening, intracranial brain shifting. Intervention is delayed for a patient with cerebral vasospasm until the vasospasm subsides.

While surgical clipping of aneurysms had previously been the only method of intervention available, neurovascular interventionalists can now use an alternative to surgery using Guglielmi Detachable Coils (GDC coils). The overall size and location of the aneurysm and the aneurysmal neck size are evaluated to decide if this option is feasible. GDC coils are microcoils composed of a soft platinum alloy that are placed with use of a microcatheter through the femoral artery. The catheter is advanced into the cerebral circulation using radiographic imaging. Low-voltage current is applied to the guidewire to detach the coil(s) placed into the sac of the aneurysm. Placement of one or more coils fills the sac, reduces the pressure inside, and isolates the aneurysm from normal circulation. When this is performed for the management of unruptured aneurysm, the patient’s hospital stay is very brief (24 to 48 hours) unless the aneurysm ruptures or another complication of angiography occurs. Endovascular treatment complications differ from those associated with surgical clipping and can include arterial dissection, arterial perforation, distal embolization, and groin hematomas. Aneurysmal recurrence has been seen in a small number of cases. However, endovascular methods have become an acceptable alternative to microsurgical clipping in appropriate cases.

Neurovascular interventionalists can also perform cerebral angioplasty for arterial vasospasm to decrease vascular narrowing and reverse ischemia in patients with new-onset vasospasm within 6 to 12 hours of onset. Patient selection for this is limited to those whose vasospasm involves accessible major cerebral vessels; distal cerebral arterial vasospasm is not amenable to angioplasty.

3. Management of hydrocephalus:

CARE PLANS FOR CEREBRAL ANEURYSM AND SUBARACHNOID HEMORRHAGE

Risk for ineffective cerebral tissue perfusion

related to vasospasm of cerebral vessels and/or decreased intracranial adaptive capacity related to increased intracranial pressure

Goals/outcomes

Maintain normal ICP and/or minimize clinical effects on cerebral adaptability through preventive measures, aggressive volume management, regulation of cerebral blood flow, and close hemodynamic monitoring.

image

Circulation Status

Risk for imbalanced fluid volume

related to initiation of measures to maintain hypervolemia

Goals/outcomes

Adequately managed intake and output with control of fluid volumes affecting systemic and cerebral blood flow and electrolyte levels

image

Fluid Balance

Fluid/electrolyte management

1. Fluid balance is maintained based on CVP, weight, and monitoring of intake/output (I&O) balance.

2. Electrolytes should be replaced on the basis of the patient’s laboratory values.

3. Hyponatremia is often seen in this patient population. Standard fluid management can make it difficult to determine whether the underlying cause is cerebral salt wasting or SIADH. Regardless of the underlying cause, hyponatremia is treated with salt repletion since the fluid restriction commonly used in other patient populations to manage SIADH is contraindicated in SAH patients who are still at high risk for vasospasm and cerebral ischemia. In mild hyponatremia, initial repletion is oral (e.g., salt tablets with meals). If hyponatremia does not respond to oral replacement, IV use of hypertonic saline (1.8% or 3%) is initiated. Hyponatremia requires frequent monitoring of laboratory values to assess effectiveness of therapy. Once the patient’s sodium normalizes, therapy is slowly tapered to assess the patient’s ability to maintain a normal serum sodium level.

4. Triple H therapy may lead to fluid volume overload and must be closely monitored. Multiple electrolyte abnormalities are often seen with triple H therapy, and serum magnesium and phosphorus levels should be monitored regularly along with standard blood chemistries.

5. Maintain adequate nutritional intake using enteral feedings, oral intake, parenteral nutrition, or lipid emulsions as indicated by patient’s neurologic status. Initially patients may present with severe nausea and vomiting following aneurysmal rupture, but this generally resolves in first 24 hours.

Additional nursing diagnoses

As appropriate, see nursing diagnoses and interventions in Nutritional Support (p. 117), Mechanical Ventilation (p. 99), Alterations in Consciousness (p. 24), Prolonged Immobility (p. 119), Emotional and Spiritual Support of the Patient and Significant Others (p. 200), Diabetes Insipidus (p. 703), and Syndrome of Inappropriate Antidiuretic Hormone (p. 734).

Care of the patient after intracranial surgery

Cranial surgery can be performed to remove a space-occupying lesion such as a tumor, evacuate a hematoma or abscess, or remove a foreign object. A patient may have a surgical repair of a vascular abnormality, such as an aneurysm or arteriovenous malformation (AVM) or to correct skull fractures. Neurosurgeon may elect to perform a procedure as a treatment modality, such as to drain CSF from the ventricular system or to divert CSF to promote dural repair, control seizures or tremors, and reduce pain. Minimally invasive intracranial procedures using stereotactic techniques are used for some biopsies and for implantation of deep brain stimulators for control of essential tremors. Endoscopic and stereotactic aspiration is being performed for noncomatose basal ganglia hemorrhages. The type of surgical approach the neurosurgeon takes depends primarily on the location of the pathologic condition. The supratentorial approach is used to remove or correct problems in the frontal, temporal, or occipital lobes, as well as in the diencephalic area (i.e., pituitary, hypothalamus). Lesions of the cerebellum and brainstem usually require an infratentorial (i.e., suboccipital) approach. The transsphenoidal approach gains access to the pituitary gland to remove a tumor, control bone pain associated with metastatic cancer, or attempt to arrest the progression of diabetic retinopathy in a patient with diabetes mellitus.

Neurologic assessment: postoperative care

Observation

LOC: The improvement in the degree of LOC depends on preoperative damage to cerebral tissue. LOC often improves as anesthesia wears off, or as cerebral edema subsides, and then the ICP approaches normal.

Pupillary changes: Pupillary abnormalities can indicate unilateral or bilateral brain dysfunction, interruption of sympathetic or parasympathetic pathways, damage in the brainstem, cranial nerve damage, and herniation.

Communicative and cognitive deficits: The ability to communicate and understand spoken or written words after surgery depends on the level of preoperative dysfunction, the site of the lesion, extent of the procedure, and the degree of postoperative cerebral edema.

CSF leakage: Assess for CSF leakage from the ear (otorrhea), from the nose (rhinorrhea) which is seen particularly with transphenoidal surgery, and also from the surgical site. The leakage of CSF indicates an open pathway to the SAS, which carries a serious risk of infection. Causes specific to craniotomy include the use of an external ventricular drainage device (which is being used as a treatment modality) and can be a source of entrance of organisms, or remote site infection, and any repeat operation. CSF leak treatment depends upon severity, site, and weighing the risk for infection and may include the use of external CSF drainage (e.g., lumbar subarachnoid drain) to divert CSF flow and thus reduce pressure, keeping patient flat (if not contraindicated), and allowing time for the dural tear to heal. Surgical intervention may be done to seal the dural leak at the origin site.

Observation and functional assessment

Collaborative management after intracranial surgery

Care priorities

12. Implement therapeutic hypothermia:

Not routine therapy but can be used. Is generally used according to a research protocol. The effects of cooling of the injured brain continues to be studied to evaluate the effects of mild to moderate hypothermia on protection against ischemic and nonischemic brain hypoxia, traumatic brain injury, and anoxic injury with cardiac arrest. Prophylactically induced hypothermia has yet to be shown as having beneficial effects on outcomes of traumatic brain injury.

CARE PLANS: COMPLICATIONS AFTER INTRACRANIAL SURGERY

Decreased intracranial adaptive capacity

related to possible changes in intracranial fluid or brain tissue volume following surgery

Goals/outcomes

Maintain normal ICP (0 to 10 mm Hg with upper limit of 15 mm Hg) through regulation of cerebral flow and cerebral spinal circulation.

image

Neurological status: consciousness

Cerebral perfusion promotion

1. Monitor for increased ICP with potential for herniation: Cerebral edema, hemorrhage, infection, and surgical trauma can all lead to increased ICP with herniation (see Box 7-1). Some cerebral edema is expected after intracranial surgery, and usually peaks about 72 hours after surgery (see Traumatic Brain Injury, p. 331). Postoperative uncontrolled nausea and vomiting can cause high intra-abdominal and also increased intrathoracic pressure (e.g., high PEEP ventilator settings) leading to high ICP.

2. Monitor for intracranial bleeding: Postoperative bleeding can be related to the surgical site and may be intracerebral, intracerebellar, subarachnoid, subdural, epidural, or intraventricular. Coagulation profiles and platelet counts should be monitored closely. Bleeding may be caused by the lengthy and extensive surgical procedure, high BP, prolonged anesthesia, preexisting medical problems, or medications. Contusions can develop after evacuation of epidural or subdural hematomas and may create a mass effect.

3. Control seizures: Generalized or partial seizures can occur as a result of surgical trauma, irritation of cerebral tissue by the presence of blood, cerebral edema, cerebral hypoxia, hypoglycemia, preexisting seizure disorder, or inadequate anticonvulsant levels. The use of anticonvulsants prophylactically remains controversial.

4. Monitor for hydrocephalus: May appear before surgery or occur after surgery as an acute or chronic complication. Usually it is caused by a slowing or complete stoppage of the flow of CSF through the ventricular system secondary to edema, bleeding, scarring, or obstruction. For further discussion, see Cerebral Aneurysm and Subarachnoid Hemorrhage (p. 629).

5. Assess for tension pneumocephalus: Uncommon but can occur as a result of air entering the subdural, extradural, subarachnoid, intracerebral, or intraventricular spaces and is an emergent situation May be a complication of infratentorial/posterior fossa craniotomy, burr holes for removal of chronic subdural hematoma, and transsphenoidal hypophysectomy. Rapid decompression is usually required.

Deficient fluid volume or excess fluid volume

related to hormonal or electrolyte imbalances

Goals/outcomes

Adequately managed I&O, control of fluid imbalances resulting from hormonal or electrolyte disturbances, and prevention of fluid loss.

image

Fluid Balance

Fluid management

1. Monitor for sodium imbalance secondary to diabetes insipidus and SIADH: results from disturbance of the hypothalamus or posterior lobe of the pituitary gland. ADH is produced in the hypothalamus and stored in the posterior pituitary.

2. Assess for hypovolemic shock: may occur as a result of general fluid loss associated with treatment using osmotic diuretics; therefore, close monitoring is essential. Critical care nurses need to be observing patients for development of DI postoperatively, because severe dehydration and hypovolemic shock can occur if fluid balance is not restored.

3. Monitor for gastrointestinal (GI) bleeding: GI bleeding associated with cerebral trauma and the postoperative period after neurosurgery can cause fluid volume deficit. Although the cause is unclear, stress from the trauma or the surgery can produce continuous vagal stimulation leading to a hyperacidic state resulting in gastric erosion, ulceration, and ultimately hemorrhage. These conditions also result from medications, especially corticosteroids (see Acute Gastrointestinal Bleeding, p. 751). Other GI conditions may occur, such as constipation, after neurologic surgery. Decreased or absent peristalsis results from prolonged anesthesia, immobility, trauma, electrolyte deficiencies, and mechanical obstruction (e.g., obstipation).

Additional nursing diagnoses

See also nursing diagnoses and interventions in Traumatic Brain Injury (p. 331), Cerebral Aneurysm and Subarachnoid Hemorrhage (p. 629) Status Epilepticus, Meningitis (p. 644), Diabetes Insipidus (p. 703), Syndrome of Inappropriate Antidiuretic Hormone (p. 734), Nutritional Support (p. 117), Prolonged Immobility (p. 149), and Emotional and Spiritual Support of the Patient and Significant Others (p. 200).

Meningitis

Pathophysiology

Meningitis is an inflammation of the brain and spinal cord (CNS) affecting the meninges (i.e., dura, arachnoid, pia), brain surface, and cranial nerves. There are several types of meningitis, broadly classified as bacterial (pyogenic), viral, aseptic, tuberculous, fungal, and parasitic. Meningitis is most commonly community acquired or the result of direct contamination. Unfortunately, the incidence of nosocomial meningitis is on the rise. The causative agent usually travels in the bloodstream from various sources before entering the CSF. The CSF is deficient in mounting any antibacterial response as it lacks immunoglobulins and complement. Therefore, when contamination of the CSF occurs, phygocytosis and opsonization of the bacteria do not occur. Bacterial meningitis, a consequence of bacterial invasion, progresses through four interconnected phases: (1) invasion of host leading to CNS infection, (2) inflammation of the subarachnoid and ventricular space as bacteria multiply, (3) pathophysiologic changes consistent with progression of inflammation, and (4) neuronal damage.

Bacterial meningitis

The most common form, can be community acquired or associated with prior infection. Other causes include injury (e.g., open/penetrating wounds), facial or basilar skull fractures, shunt occlusion/malfunction, craniotomy, otitis media, sinusitis, or bacteremia (e.g., endocarditis, pneumonia).

Streptococcus pneumoniae, a gram-positive cocci, has been the leading cause of adult meningitis in the United States. Pneumococcal meningitis occurs in crowded conditions and is spread seasonally (fall and winter). This organism is not as prevalent as a cause of meningitis since the development of Pneumovax and Prevnar vaccines. Pneumococcal meningitis may occur following an upper respiratory tract infection (URI) or nasopharyngeal colonization with a pneumococcal strain, is a complication of conditions associated with CSF leaks, is associated with asplenia, and is more prevalent in immunocompromised persons and in older adults.

Neisseria meningitidis, a gram-negative cocci, is the second leading cause of meningitis in adults. Infection is more likely to occur in patients with complement component deficiencies (e.g., congenital or associated with nephrotic syndrome, hepatic failure, systemic lupus erythematosus, multiple myeloma).

Haemophilus influenzae, a gram-negative bacilli, is the most common cause in children; however, it may affect adults. Predisposing factors include URIs, hypogammaglobulinemia, diabetes mellitus, alcoholism, and head trauma. Since 1990, the H. influenzae vaccine type B (Hib vaccine) has reduced the incidence of bacterial meningitis substantially in infants and children, making it a disease predominantly of adults. Prior to 1990, H. influenzae type b was the leading cause of bacterial meningitis.

imageListeria monocytogenes, gram-positive bacilli, is being seen more frequently as a cause of meningitis, especially in immunocompromised patients and those of extreme ages (very young and very old). Outbreaks have been linked to consumption of contaminated dairy products, undercooked chicken, fish, and meats.

imageGram-negative species (Escherichia coli, Klebsiella, Proteus, and Pseudomonas) are increasing in prevalence as a nosocomial cause secondary to trauma or neurosurgical procedures. Spontaneous gram-negative meningitis is found in older adults, the immunocompromised, or persons with underlying conditions such as cirrhosis, diabetes, malignancy, or splenectomy. The urinary tract is the usual portal of entry of bacteria.

Neurologic assessment: meningitis

Goal of system assessment

A complete neurologic examination should be performed to establish the patient’s baseline neurologic function. One or more tests for meningitis usually are positive (seeTable 7-2). Examination of associated systems (head, eye, ear, nose, and throat [HEENT] and pulmonary) provides additional data.

Table 7-2 POSITIVE MENINGEAL SIGNS

Test/Description Positive Findings
Stiff neck sign (nuchal rigidity): Raise patient’s head by flexing the neck and attempting to make the patient’s chin touch the sternum. Pain and resistance to neck motion
Brudzinski sign: Assess for nuchal rigidity. Flexion of the hips and knees when the examiner flexes the patient’s neck
Kernig sign: Flex the patient’s leg at the knee and hip when the patient is supine, and then attempt to straighten the leg. Pain in the lower back and resistance to straightening the leg

Bacterial meningitis presents with classic symptoms of fever, altered mental status, headache, and nuchal rigidity. Immediate diagnosis and isolation of the organisms are paramount in this life-threatening disease. Delay in obtaining the necessary information needed to diagnosis and treat the underlying organism will increase morbidity and mortality.

Observation

Meningeal signs (see Table 7-2):

Clinical presentation

S. pneumoniae: The classic presentation of pneumococcal meningitis is fever, headache, meningismus, and altered mental status that progresses quickly to coma. Nuchal rigidity and Kernig or Brudzinski sign are present. Nausea, vomiting, profuse sweats, weakness, myalgia, seizures, and cranial nerve palsies also may be present.

N. meningitidis: Patients may quickly deteriorate, beginning with fever and early macular erythematous rash that progresses rapidly to petechial and purpuric states, conjunctival petechiae, and aggressive behavior. Dysfunctions of cranial nerves VI, VII, and VIII (see Appendix 4) and aphasia, ventriculitis, subdural empyema, cerebral venous thrombosis, and disseminated intravascular coagulation (DIC) may occur.

H. influenzae: The most distinguishing sign is early development of deafness, which can occur within 24 to 36 hours after onset. A morbilliform or petechial rash may be present.

imageL. monocytogenes: Seizures and focal deficits such as ataxia, cranial nerve palsies, and nystagmus are seen early in the course of infection. Conclusive diagnosis may require serology testing.

imageGram-negative species: In older adults, fever may be absent or low grade and headache may not be reported. Meningeal signs may be subtle, but confusion, severe mental status changes, and pneumonia are commonly reported. Nuchal rigidity in older adults must be differentiated from degenerative changes of the cervical spine.

B. burgdorferi: The symptoms of meningitis may be preceded by symptoms of Lyme disease, which occur in three stages. The first stage is a “bull’s eye” rash within a few days of the tick bite followed by headache, stiff neck, lethargy, irritability, and changes in mental status, especially memory loss. Stage two, weeks to months after the tick bite, causes persistent headache, nausea, vomiting, malaise, irritability, cranial nerve deficits, mental status changes, peripheral neuropathies, and myalgias. In the last or third stage, arthritic types of symptoms and brain parenchymal changes are apparent.

Acute meningitis with negative Gram stain: Fever and neck stiffness are the most frequent findings. The Gram stain for bacteria is negative, but CSF WBC count is elevated. Symptoms are similar to those for other types of meningitis.

M. tuberculosis: A slow-onset process that causes neurologic damage before treatment is sought. Symptoms include headache, lethargy, confusion, nuchal rigidity, cranial nerve abnormalities, SIADH, weight loss, and night sweats. Kernig and Brudzinski signs are present. The chest radiographic results may be clear, and purified protein derivative (PPD) may be nonreactive.

Cryptococcus neoformans: Because the infection is subacute, fever and headache may have a subtle pattern lasting for weeks while other symptoms of meningitis occur, including positive meningeal signs (Table 7-2), alterations in mental status (e.g., hyperactivity, bizarre behavior, emotional lability, poor judgment), photophobia, focal cranial nerve deficits, nausea, vomiting, and (rarely) seizures.

Aseptic meningitis syndrome: Fever, headache, stiff neck, fatigue, anorexia, and altered LOC are seen several hours after ingestion of causative drug. Severity varies with amount of drug taken and previous exposures. CSF glucose may be slightly elevated.

Functional assessment

Diagnostic tests

Bacterial meningitis presents with classic symptoms of fever, altered mental status, headache, and nuchal rigidity. Immediate diagnosis and isolation of the organisms are paramount in this life-threatening disease. Delay in obtaining the necessary information needed to diagnosis and treat the underlying organism will increase morbidity and mortality.

Diagnostic Tests for Meningitis

Test Purpose Abnormal Findings
Imaging
Computed tomography (CT) of brain
Do not delay lumbar puncture or administration of antibiotics for the CT scan, especially if the history does not support traumatic injury or an expanding intracranial lesion.
Assess details of structures of bone, tissue, and fluid-filled spaces. Detects exudate, abscesses, and intracranial pathology (e.g., tumors, brain injury). Assess for hydrocephalus. Shift of structures due to enlarged mass, edema, exudate, abscesses, fresh hemorrhage, hematomas, infarction, hydrocephalus. Can visualize facial skeleton and soft tissue structures for abnormalities (e.g., tumors, brain injury).
Magnetic resonance imaging (MRI) of brain Minute oscillations of hydrogen atoms in brain create graphic image of bone, fluid, and soft tissue. Provide a more detailed image. MassesDetects exudate, abscesses, and intracranial pathology (e.g., tumors, brain injury).
Laboratory Testing
Serum CBC with WBC count and differential Assesses for presence of infection Elevated WBCs
CSF analysis
An LP should not be done following head injury, if focal neurologic deficits or papilledema are present, since these signs indicate increased ICP (see Box 7-1). Antibiotic therapy should not be delayed if CSF samples cannot be obtained.
Polymerase chain reaction (PCR) assays antibody titers
A DNA-based CSF test to check for the presence of certain causes of meningitis includes HSV1, HSV2, VZV, HIV, Epstein-Barr virus (EBV), West Nile virus, cytomegalovirus (CMV), HHV-6.
Other CSF studies
Venereal Disease Research Laboratories (VDRL)
Fluorescent Treponemal Antibody-Absorption (FTA-ABS) (evaluates for syphilis)
The most important laboratory test for diagnosing meningitis. CSF may be obtained through an intraventricular catheter, ventriculostomy and reservoir via cervical approach, or lumbar puncture(LP).
Note: Clinical signs of improvement rather than repeat CSF analysis is a better indicator of treatment response. However, repeat LP if: 1) there is no clinical improvement within 24–72 hrs after treatment is initiated; 2) it is performed 2-3 days after initiation of treatment if microorganisms are resistant to standard therapy; and 3) fever persists for greater than 8 days.
The CSF is analyzed for cell count with white cell differential, glucose, protein, Gram’s stain, acid-fast stain, culture, and sensitivity (Table 7-3). CSF studies include the following:

Blood, urine, and sputum cultures Help identify the infecting organisms and determine if there is a bacteremia, urinary tract infection, or respiratory infection Presence of infecting organisms in the bloodstream, urinary tract or lungs/upper airways

Collaborative management

Care priorities

1. Control infection

Table 7-4 COMMON DRUG THERAPY FOR THE MANAGEMENT OF MENINGITIS

Causative Agent Characteristic Therapy
Bacterial Meningitis
S. pneumoniae Gram-positive cocci Penicillin (PCN), ceftriaxone, cefotaxime, vancomycin with ceftriaxone if beta-lactam resistance; chloramphenicol for PCN allergies
H. influenzae Gram-negative bacilli Cefotaxime or ceftriaxone, add rifampin if pharyngeal colonization
N. meningitides Gram-negative cocci Penicillin G, add rifampin, fluoroquinolones, or cephalosporin if pharyngeal colonization; alternative is third-generation cephalosporin (cefotaxime)
L. monocytogenes Gram-positive bacilli Penicillin G or ampicillin with gentamycin for synergy; if allergy to PCN, then trimethoprim-sulfamethoxazole
M. tuberculosis Acid-fast bacteria Isoniazid, rifampin, ethambutol, pyrazinamide
B. burgdorferi Spirochete Ceftriaxone or penicillin G
Fungal
C. neoformans Fungus Amphotericin B + flucytosine, fluconazole, or itraconazole
Cocci
  Gram-positive Vancomycin + penicillin G + aminoglycosides
  Gram-negative Penicillin G
Bacilli
  Gram-positive Ampicillin, penicillin + aminoglycosides
P. aeruginosa, Klebsiella, E. coli, Citrobacter, Acinetobacter, Enterobacter, Serratia marcescens Gram-negative High doses of third-generation cephalosporins + aminoglycosides

Data from Fekete T, Quagliarello V: Treatment and prevention of bacterial meningitis in adults. http:www.uptodate.com ; Friedman N, Sexton D: Epidemiological and clinical features of Gram-negative bacillary meningitis. http:www.uptodate.com; and Frankel and Hartman (2004)

9. Evaluate the need for support services:

Evaluate the need for home health care, support groups, and social services.

CARE PLANS: MENINGITIS

Decreased intracranial adaptive capacity

related to altered fluid dynamics secondary to brain and spinal cord inflammation

Goals/outcomes

Within 72 hours of initiation of antimicrobial therapy, patient’s ICP returns to normal range as evidenced by orientation to time, place, and person; bilaterally equal and normoreactive pupils; bilaterally equal strength and tone of extremities; absence of cranial nerve palsies; RR 12 to 20 breaths/min with normal depth and pattern; HR 60 to 100 beats/min (bpm); BP within patient’s normal range; and absence of headache, vomiting, papilledema, and other clinical indicators of increased ICP. After instruction, patient verbalizes knowledge of the importance of avoiding Valsalva-like activities.

image

Neurological Status

Additional nursing diagnoses

See Risk for Trauma (Oral and Musculoskeletal) in Status Epilepticus (p. 672). Because these patients are at risk for SIADH, see Syndrome of Inappropriate Antidiuretic Hormone, p. 734. See SIRS, Sepsis, and MODS, p. 924, since these patients are at risk for septic shock; Nutritional Support, p. 117, Prolonged Immobility, p. 149, and Emotional and Spiritual Support of the Patient and Significant Others (p. 200).

Neurodegenerative and neuromuscular disorders

Pathophysiology

Neurodegenerative diseases are conditions wherein the neurons, or the myelin sheath of the neurons of the brain and spinal cord, are destroyed. Cells of the brain and spinal cord do not effectively regenerate in large numbers, so profound destruction is sometimes devastating. Over time, the progressive destruction leads to dysfunction and disabilities. The disorders are divided into two groups; conditions affecting movements (e.g., ataxia) and conditions affecting memory (e.g., dementia), which are not mutually exclusive. Alzheimer, Pick, Parkinson, Huntington, and Lou Gehrig (amytrophic lateral sclerosis [ALS]) diseases, prion diseases (Cruetzfeldt-Jakob [CJD]), and multiple sclerosis are a few of the more commonly recognized conditions. Some of the diseases are genetic, while alcoholism, cancer, and vascular disease are associated with other conditions. Environmental toxins, chemicals, or viruses may cause other disorders. Neurodegeneration often begins long before the patient manifests symptoms. Treatments vary with each disorder.

Neuromuscular disorders include the neurodegenerative diseases, which affect voluntary movements. Communication between the nervous system and muscles is not possible when nerves are destroyed. Muscles weaken and atrophy due to disuse. Weakness may also be associated with muscle twitching, cramps, and pain, along with joint and movement deficits. These disorders may affect the heart and respiratory muscles. Many neuromuscular disorders are genetic, while others are immune mediated, associated with an immunologic disorder. Myasthenia gravis (MG) Guillain-Barr´e Syndrome (GBS) and muscular dystrophy are several of the more commonly recognized conditions. Most of the diseases are incurable. The goal of treatment is to improve symptoms, increase mobility, and lengthen life. Patients with MG may experience difficulties with medication management resulting in a crisis, which is rather easily corrected with the proper medication adjustment. Patients with other neuromuscular disorders may require more elaborate treatments including high-dose corticosteroids, plasmapheresis, and more prolonged hospitalization.

Diagnosis of neuromuscular diseases depends on identification of a specific defect of neuromuscular function. The functional defect can sometimes be inferred by a physical examination done by a physician or midlevel practitioner coupled with laboratory testing of blood and possibly CSF. A more extensive diagnostic process evaluates the function of nerves, muscles, and the connections between them by using two complementary techniques—nerve conduction velocity testing (NCVs) and electromyography (EMGs).

Care of critically ill patients may involve managing patients with respiratory failure and cardiovascular instability related to exacerbations of neuromuscular disorders. Patients at this stage of instability may be terminally ill. Patients with either MG or GBS (GBS) may be treated and fully recovered. The chapter will focus on MG and GBS; however, the nursing diagnoses, interventions, and outcomes are common to most neurodegenerative and neuromuscular disorders.

Myasthenia gravis

Pathophysiology

imageMG is a chronic, progressive autoimmune disorder causing weakness and abnormal fatigability of the voluntary striated skeletal muscles. MG usually affects women between 20 and 40 years of age and men after age 40; the peak incidence for women is during the second and third decades and for men during the sixth decade. The overall ratio of affected women to men is 3:2. Of patients with MG, 85% to 90% have an anti–acetylcholine receptor (AChR) antibody (immunoglobulin). MG is associated with other autoimmune disorders. The thymus gland undergoes pathologic changes in 80% of MG patients and may produce anti-AChR antibodies when exposed to inflammation. The course of the disease depends on the muscle groups involved and the degree of their involvement.

MG causes changes in the structural integrity of the postsynaptic membrane at the neuromuscular junction by markedly reducing the number of AChRs. Acetylcholine (ACh), a neurotransmitter, is synthesized and stored in the terminal expansion of motor nerve axons. ACh is released into the synaptic cleft. The attachment of ACh to AChR on the postsynaptic membrane activates muscle action potential, resulting in muscle contraction. Contraction terminates when ACh is deactivated by acetylcholinesterase in the neuromuscular junction.

Patients may experience remissions and exacerbations. Many medications can increase the weakness associated with MG, including several commonly administered antibiotics (erythromycin, aminoglycosides, and azithromycin) and cardiac medications such as magnesium or antidysrhythmic agents including procainamide, beta adrenergic–blocking agents, and quinidine. Paradoxical weakness may occur when a patient receives an excessive dose of anticholinesterase medications (cholinesterase inhibitors such as physostigmine or neostigmine), which are used to treat MG. Distinguishing worsening MG from side effects from prescribed medication effects can be difficult. Exacerbations can be profound, and thus are called crises.

A myasthenic or cholinergic crisis may occur rapidly or incipiently. Myasthenic crisis can occur as part of the natural course of myasthenia gravis or may result from other factors, including infection, tapering of immunosuppressive medications, administration of various other medications, pregnancy, childbirth, or following a surgical procedure, ultimately resulting in respiratory failure from weakness of the respiratory muscles. Severe weakness of the oropharyngeal muscles (bulbar signs) is often associated with respiratory muscle weakness, resulting in dysphagia and aspiration. Endotracheal (ET) intubation with mechanical ventilation may be needed. A cholinergic crisis results from excessive dosing of anticholinesterase medications and rarely occurs if the dose of medications remains within the normally prescribed range. The patient is acutely aware of all sensations. Crisis is dramatic and frightening.

Assessment

Symptom progression

Auscultation

Diagnosis of Myasthenic or Cholinergic Crisis

Test Purpose Abnormal Findings
Tensilon (edrophonium) test
With MG, weakness and muscle fatigue will improve within 30 to 60 seconds of receiving IV Tensilon injection (2 to 10 mg), and improvement will last up to 5 minutes.
Identifies the type of crisis. Tensilon is a short-acting anticholinesterase agent that delays hydrolysis of acetylcholine, permitting the acetylcholine released by the nerve to act repeatedly over a longer period. Myasthenic crisis: Weakness improves with edrophonium chloride (Tensilon) versus Cholinergic crisis: Symptoms worsen with Tensilon. Test is done by a neurologist who assesses the patient’s immediate response.
Caution: Have atropine sulfate at the bedside during Tensilon test to reverse the effects of Tensilon if the patient is in cholinergic crisis.
Serum antibody titer Correlation between titer and disease severity and course has not been proved. Assesses for presence of serum antibodies against acetylcholine receptors Elevated serum antibodies against are present in 80% to 90% of cases of generalized MG.
Electromyography (EMG) Muscle action potentials are recorded from selected skeletal muscles. Tests muscle action potentials, reflective of ability to contract The amplitude of the evoked muscle action potentials falls rapidly in persons with MG.
Mediastinal magnetic resonance imaging (MRI) of the thymus gland or mediastinoscopy To evaluate for thymic abnormalities, present in 80% of patients with MG 65% to 90% have thymic hyperplasia, whereas 10% to 15% have gross or microscopic thymomas.
Thyroid studies
Thyroid abnormalities are often present in young women.
Evaluate for hyperthyroidism. MG is associated with Hashimoto thyroiditis, an autoimmune thyroid disorder.
Other laboratory studies: Creatine phosphokinase (CPK), erythrocyte sedimentation rate (ESR), and antinuclear antibody levels: There is a frequent concurrence of other immunologic disorders with MG.

Collaborative management

Care priorities for patients with myasthenia gravis

1. Manage respiratory failure:

ET intubation with mechanical ventilation may be necessary, depending on the degree of involvement of the respiratory muscles. (See Mechanical Ventilation, p. 99.) Bilevel positive pressure ventilation (BiPAP) may also be used effectively in a subset of patients, if able to breathe somewhat effectively.

4. Manage pharmacotherapy during noncrisis periods:

Medications must be given on time to maintain therapeutic effects. Drug combinations are patient-specific.

Cholinesterase inhibitors: Pyridostigmine bromide (Mestinon), neostigmine bromide (Prostigmin), and ambenonium chloride (Mytelase) are used to inhibit the hydrolysis of ACh by acetylcholinesterase at the neuromuscular junction. Pyridostigmine is often used, since it has fewer side effects and is longer acting. The patient is given a dose every 3 hrs during the day, and the dose is adjusted based on effects. Sustained-release preparations usually are given at bedtime to maintain the patient’s strength throughout the night and early morning hours.

Immunosuppression: Glucocorticosteroids (e.g., ACTH and prednisone) and other immunosuppressive agents: Glucocorticosteroids are used alone or in conjunction with anticholinesterase drugs. They provide clinical improvement for 70% to 100% of patients with MG who refuse thymectomy and have weakness uncontrolled by anticholinesterase drugs. Although the mechanism of action of steroids is uncertain, studies indicate they directly influence neuromuscular transmission, suppress the action of the immune system by decreasing the size of the thymus gland and lymphatic tissue, decrease circulating lymphocytes, and decrease antireceptor reactivity of peripheral lymphocytes. Treatment is continued indefinitely. Glucocorticosteroids produce favorable results in all patients with muscle involvement, from ocular to severe respiratory impairment. Azathioprine (Imuran) may be used alone or in combination with other therapies in situations in which response to steroids is poor. Side effects of azathioprine include toxic hepatitis, thrombocytopenia, leukopenia, leukemia, lymphoma, infections, vomiting, and teratogenic effects.

Immune globulin: Routine use of human immune globulin (IG) is not recommended, but administration of IV immunoglobulin (IVIg) may be considered in patients with severe MG for whom other treatments have been unsuccessful or are contraindicated.

Share this: